NYSE:PFEPharmaceuticals
Pfizer (PFE) Stock Looks Fully Priced After Its 21% Slump
Pfizer stock sits in an awkward middle ground for valuation right now, with a roughly 21% share price decline over five years set against checks that suggest the current price looks neither clearly cheap nor clearly expensive.
Over the past five years, Pfizer shares have declined about 21%, which means long term holders have not been rewarded for their patience so far.
Regulatory progress in areas like oncology and weight loss can support higher earnings expectations, while ongoing pricing...